Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vertex (VRTX) PT Raised to $234 at BMO Capital
February 6, 2019 7:53 AM ESTBMO Capital analyst Do Kim raised the price target on Vertex (NASDAQ: VRTX) to $234.00 (from $192.00) while maintaining a Outperform rating.
Kim commented, "Our target price rises to $234 from $192, as we increase long-term CF revenue projections, following another solid 4Q18 beat on revenues and... More
Vertex (VRTX) PT Raised to $220 at Cowen
February 6, 2019 7:52 AM ESTCowen analyst Phil Nadeau raised the price target on Vertex (NASDAQ: VRTX) to $220.00 (from $210.00) while maintaining a Outperform rating.
The analyst commented, "VRTX reported Q4 CF franchise revenue of $868.2MM vs consensus of $818.8MM, non-GAAP EPS of $1.30 vs. consensus of $1.08. 2019 revenue guidance... More
Maxim Group Downgrades Vertex (VRTX) to Hold
February 6, 2019 7:45 AM ESTMaxim Group analyst Jason McCarthy downgraded Vertex (NASDAQ: VRTX) from Buy to Hold.
The analyst highlighted:
Vertex reported 4Q18 with cystic fibrosis (CF) revenue of $868M, representing sequential growth of 11% and beating consensus of $816M; the results include Kalydeco revenue of $259M vs. $250.5M... MoreVertex (VRTX) PT Lowered to $213 at RBC Capital
February 6, 2019 7:14 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Vertex (NASDAQ: VRTX) to $213.00 (from $215.00) while maintaining a Outperform rating.
... MoreVertex Pharma (VRTX) Tops Q4 EPS by 24c, Revenues Beat; Offers FY19 Revenue Guidance
February 5, 2019 4:03 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $1.30, $0.24 better than the analyst estimate of $1.06. Revenue for the quarter came in at $868 million versus the consensus estimate of $819.12 million.
"Our achievements in 2018 were marked by a significant increase in the number of CF... More
